Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Healthcare Biotechnology
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Waverley Pharma Inc > MC $8 M / 5 Cancer Drug approved /2 BIG Drug approval in Q4
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by Aman0808on Aug 12, 2020 1:02pm
148 Views
Post# 31398785

RE:RE:MC $8 M / 5 Cancer Drug approved /2 BIG Drug approval in Q4

RE:RE:MC $8 M / 5 Cancer Drug approved /2 BIG Drug approval in Q4Thanks for posting this. Looking to get it and was hoping my understanding is correct that WAVE needs to wait until the patents expire and then they will have a sales pipeline of teh generic version of the drug?

Below are the expiries from their corp presentation:

UK Marketed Generic Drugs: (Patents expired)
  1. Capecitabine
  2. Temozolomide
  3. Erlotinib
UK Approved & EU Pending Approval Generic Drugs:
  1. Bortezomib – is a chemotherapy drug used to treat multiple myeloma (patent expiry Q1 2022)
  2. Pemetrexed – is a chemotherapy drug used to treat lung cancer (patent expiry Q3 2021)
US Filed ANDA Generic Drugs:
  1. WAV-101 – is a chemotherapy drug; brand sales are > 1 billion USD (patent expiry Q3 2022).
  2. WAV-102 – is a chemotherapy drug; brand sales are > 800 million USD (patent expiry Q3 2022)
If my understanding is correct, then lots will be coming online in 2022-early 2023
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities